Global Acute Heart Failure (AHF) Therapeutics IndustrySacramento BeeThis report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Eu…
WHO CAN DONATE ORGANS: Just about anyone, at any age, can become an organ donor. Anyone younger than 18 needs to have the consent of a parent or guardian. For organ donation after death, a medical assessment will be done to determine what organs can be…
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for …Equities.com… R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; an…
TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third …NASDAQ… the company's novel third-generation anti-CD20 monoclonal antibody, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) who wer…
Study evaluates prognostic utility of novel biomarkers of cardiovascular stressNews-Medical.netThe Framingham Heart Study Cohort evaluated over 3,400 individuals to determine the prognostic utility of ST2 individually, and when combined with other biom…
NEW YORK, Sept. 5, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Global Medical Laboratories Industry http://www.reportlinker.com/p0960414/Global-Medical-Laboratories-Industry.html#ut…
Wall Street Journal (India)Bayer challenges compulsory licence issued by IndiaChannel News AsiaOver 25,000 patients suffering from liver and kidney cancer die every year in India. Doctors said at least half of them could be saved with timely diagnosis …
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for …The Herald | HeraldOnline.com… R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 cl…
Pluristem stem cells save 3rd bone marrow disease patientGlobesDue to the patient's life threatening condition, 144 days after the bone marrow transplantation, PLX cells were twice injected intramuscularly, one week apart. No local or systemic side…
The 45-year old man suffered from bone marrow failure after undergoing chemotherapy and a bone-marrow transplant, due to leukemia.